Dhaka, Nov. 22 -- Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.

A more than 35 per cent rally in the company's stock this year has largely been driven by the explosive growth of the weight-loss drug market.

In the last two years, as new, highly effective obesity treatments hit the market, the category has emerged as one of the most lucrative segments in healthcare.

Sales of Lilly's tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity, have also topped Merck's Keytruda as the world's best-selling drug.

Novo Nordisk had the early lead in the space, but Mounjaro and Zep...